Trial Profile
Phase II Study Of Herceptin And Exemestane For Treatment Of Postmenopausal Women With Metastatic Hormone-Responsive, HER2/NEU Positive Breast Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2011 New trial record